The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2020 | Intracranial activity of selpercatinib in RET fusion positive NSCLC

Name: Intracranial activity of selpercatinib in RET fusion positive NSCLC
Uploaded: 2020-05-25T00:00:00Z
Duration: 7 min 34 s
Description: Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, described the LIBRETTO-001 study (NCT03157128), a phase I/II study of selpercatinib, a RET inhibitor, in patients with RET fusion positive NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Vivek Subbiah • 25 May 2020

ASCO 2020

Lung Cancer Non-Small Cell Lung Cancer Selpercatinib

LIBRETTO-001

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, described the LIBRETTO-001 study (NCT03157128), a phase I/II study of selpercatinib, a RET inhibitor, in patients with RET fusion positive NSCLC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).